Discover

AKYA
Akoya Biosciences, Inc.
1.29
undefined x undefined
undefined x undefined
bid
ask
+
0.00
0.00%
04:00 PM
Ytd
1y
1.29
day range
1.60
1.88
52 week range
6.31
Open1.39Prev Close1.29Low1.29High1.60Mkt Cap119.45M
Vol704.17KAvg Vol233.37KEPS-1.16P/EN/AForward P/E-4.38
Beta1.35Short Ratio13.43Inst. Own70.19%DividendN/ADiv YieldN/A
Ex Div DateN/AEarningN/A50-d Avg2.63200-d Avg2.911yr Est3.50
Earning
DateForEstimateReportedSurprisesurprise %
2024-11-142024-09-0.19-0.180.015.26%
2024-08-052024-06-0.27-0.27N/AN/A
2024-08-052024-06-0.27N/AN/AN/A
2024-05-132024-03-0.3-0.35-0.05-16.67%
2024-05-132024-03-0.3N/AN/AN/A
2024-03-042023-12-0.27-0.220.0518.52%
Upgrade / Downgrade
DateFirmActionFromTo
2024-11-19Piper SandlerUpgradeOverweightOverweight
2024-11-15Craig-HallumDowngradeBuyHold
2024-11-15Canaccord GenuityUpgradeBuyBuy
2024-08-13Piper SandlerUpgradeOverweightOverweight
2024-08-06Morgan StanleyDowngradeOverweightEqual-Weight
2024-08-06BTIGDowngradeBuyNeutral
Profile
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. It has a collaboration agreement with NeraCare that enables personalized therapy selection for early-stage melanoma patients. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Insider Holder
DateNameRelationQuantityDescription
2024-11-18BAMFORD PASCALOfficer210.26KStock Award(Grant)
2024-11-18EK JOHN FREDERICKChief Financial Officer288.23KStock Award(Grant)
2024-11-18KAMOCSAY JENNIFEROfficer186.72KStock Award(Grant)
2024-11-18MCKELLIGON BRIAN MChief Executive Officer443.48KStock Award(Grant)
2023-06-11MENDEL SCOTTDirector28.50KPurchase
2024-02-21PLA FREDERICChief Operating Officer123.51KStock Award(Grant)
Institution Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Blue Water Life Science Advisors, Lp4.70M11.32M9.48%
2024-09-29Blackrock Inc.1.58M3.81M3.19%
2024-09-29Vanguard Group Inc1.48M3.58M3.00%
2024-09-29Paragon Associates & Paragon Associates Ii Joint Venture790.00K1.90M1.59%
2024-09-29Geode Capital Management, LLC561.61K1.35M1.13%
2024-09-29State Street Corporation453.30K1.09M0.91%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2024-09-29Vanguard Total Stock Market Index Fund882.32K2.13M1.78%
2024-10-30iShares Russell 2000 ETF649.39K1.57M1.31%
2024-09-29Vanguard Extended Market Index Fund306.11K737.73K0.62%
2024-08-30Fidelity Small Cap Index Fund271.49K654.30K0.55%
2024-10-30iShares Russell 2000 Growth ETF212.34K511.73K0.43%
2024-10-30Fidelity Extended Market Index Fund127.00K306.07K0.26%